Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.
Zhao TX, Sriranjan RS, Tuong ZK, Lu Y, Sage AP, Nus M, Hubsch A, Kaloyirou F, Vamvaka E, Helmy J, Kostapanos M, Jalaludeen N, Klatzmann D, Tedgui A, Rudd JHF, Horton SJ, Huntly BJP, Hoole SP, Bond SP, Clatworthy MR, Cheriyan J, Mallat Z. Zhao TX, et al. Among authors: hubsch a. NEJM Evid. 2022 Jan;1(1):EVIDoa2100009. doi: 10.1056/EVIDoa2100009. Epub 2021 Nov 22. NEJM Evid. 2022. PMID: 38319239 Clinical Trial.
Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial.
Zhao TX, Kostapanos M, Griffiths C, Arbon EL, Hubsch A, Kaloyirou F, Helmy J, Hoole SP, Rudd JHF, Wood G, Burling K, Bond S, Cheriyan J, Mallat Z. Zhao TX, et al. Among authors: hubsch a. BMJ Open. 2018 Sep 17;8(9):e022452. doi: 10.1136/bmjopen-2018-022452. BMJ Open. 2018. PMID: 30224390 Free PMC article.
GLP-1 Is a Coronary Artery Vasodilator in Humans.
Clarke SJ, Giblett JP, Yang LL, Hubsch A, Zhao T, Aetesam-Ur-Rahman M, West NEJ, O'Sullivan M, Figg N, Bennett M, Wewer Albrechtsen NJ, Deacon CF, Cheriyan J, Hoole SP. Clarke SJ, et al. Among authors: hubsch a. J Am Heart Assoc. 2018 Nov 20;7(22):e010321. doi: 10.1161/JAHA.118.010321. J Am Heart Assoc. 2018. PMID: 30571482 Free PMC article.
Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers - a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale.
Kostapanos MS, Cacciottolo PJ, Hubsch A, Pavey H, Hurlock J, Maki-Petaja K, Wilkinson IB, Cheriyan J. Kostapanos MS, et al. Among authors: hubsch a. J Drug Assess. 2019 Oct 9;8(1):167-174. doi: 10.1080/21556660.2019.1677673. eCollection 2019. J Drug Assess. 2019. PMID: 31692938 Free PMC article.
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM, Fisk M, Miles K, Kaloyirou F, Hubsch A, Smith J, Wilkinson IB, Cheriyan J. McEniery CM, et al. Among authors: hubsch a. Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4. Trials. 2020. PMID: 32616067 Free PMC article.
Correction to: ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM, Fisk M, Miles K, Kaloyirou F, Hubsch A, Smith J, Wilkinson IB, Cheriyan J. McEniery CM, et al. Among authors: hubsch a. Trials. 2020 Jul 14;21(1):641. doi: 10.1186/s13063-020-04578-7. Trials. 2020. PMID: 32665001 Free PMC article.
Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.
Cacciottolo PJ, Kostapanos MS, Hernan Sancho E, Pavey H, Kaloyirou F, Vamvaka E, Helmy J, Hubsch A, McEniery CM, Wilkinson IB, Cheriyan J. Cacciottolo PJ, et al. Among authors: hubsch a. BMJ Open. 2021 Apr 13;11(4):e037457. doi: 10.1136/bmjopen-2020-037457. BMJ Open. 2021. PMID: 33849844 Free PMC article.
Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial.
Sriranjan R, Zhao TX, Tarkin J, Hubsch A, Helmy J, Vamvaka E, Jalaludeen N, Bond S, Hoole SP, Knott P, Buckenham S, Warnes V, Bird N, Cheow H, Templin H, Cacciottolo P, Rudd JHF, Mallat Z, Cheriyan J. Sriranjan R, et al. Among authors: hubsch a. BMJ Open. 2022 Oct 7;12(10):e062602. doi: 10.1136/bmjopen-2022-062602. BMJ Open. 2022. PMID: 36207050 Free PMC article.
38 results